drugset
drugset / Trial / NCT05079503

Gut Microbiome and Its Immune Modulation in Locally Advanced Rectal Cancer

NCT05079503 ↗

Unknown 40 enrolled Korean Cancer Study Group
NaSingle-groupOpen-labelTreatment

Summary

To investigate dynamic change of gut microbiomes and metabolites, and their effects on immune modulation. To evaluate the efficacy and safety of TNT with GEN-001 (Lactococcus lactis) and identify predictive biomarkers for pathologic response in patients with locally advanced rectal cancer (LARC).

Timeline

Start
2021-12-15
Primary completion
2023-08-30
Completion
2024-01-30

Drugs

EvaluationDrugModalityDoseRoute
Subject GEN-001 Other / unclassified — Oral

Indications

No indication recorded.